C4 Therapeutics, Inc.

C4 Therapeutics, Inc. - Fiscal Year 2025 Annual Review (10-K Summary)

C4 Therapeutics, Inc.'s latest 10-K filing offers a detailed look into its performance and strategic direction for the fiscal year ended December 31, 2025. This summary highlights key insights for investors.

Business Overview (Company Overview and Core Strategy)

C4 Therapeutics, a clinical-stage biotechnology company, develops novel therapies using targeted protein degradation (TPD). Its proprietary TORPEDO™ platform harnesses the body's natural protein disposal system to selectively remove disease-causing proteins. This innovative approach shows promise for treating a wide range of illnesses, including cancer.

The company pursues a core strategy:

1. Advancing its internal pipeline: C4 Therapeutics progresses lead drug candidates through preclinical and clinical development.
2. Forming strategic collaborations: The company partners with larger pharmaceutical companies to validate its technology, share development costs and risks, and leverage broader resources for drug discovery and commercialization. These partnerships are crucial for funding and expanding the TPD platform's reach.

Financial Performance (Fiscal Year Ended December 31, 2025)

As an early-stage biotech company, C4 Therapeutics prioritizes research and development and has not yet achieved profitability.

• Revenue: The company primarily earns revenue from collaboration agreements. This revenue includes upfront payments, research funding, and milestone achievements from partnerships.
• Net Loss: C4 Therapeutics reported a net loss for fiscal year 2025. This reflects substantial investment in research and development.
• Operating Expenses:
  • Research and Development (R&D): R&D expenses were the main driver of spending in 2025. This reflects the company's efforts to advance its pipeline, including clinical trial costs and platform development.
  • General and Administrative (G&A): G&A expenses supported corporate functions and overhead in 2025.

Financial Health (Cash, Liquidity, and Debt)

• Cash Position and Funding: As of December 31, 2025, C4 Therapeutics held cash, cash equivalents, and marketable securities.
  • Cash Used in Operations: The company used cash for operating activities during 2025.
  • Equity Financings: To fund operations and pipeline advancement, C4 Therapeutics actively raised capital. In 2024 and 2025, the company completed an Underwritten Public Offering and used an At-The-Market (ATM) Equity Program. These efforts involved issuing new shares and generated gross proceeds. Such equity issuances dilute existing shareholders by increasing the total number of shares outstanding.
  • Cash Runway: Based on current cash and projected spending, management estimates their existing capital can fund operations for a period. However, future capital raises will likely be needed to continue development and commercialization efforts.
  • Debt: The company reported no significant long-term or short-term debt obligations as of December 31, 2025.
• Market Capitalization & Shares Outstanding: As of February 23, 2026 (the filing date), C4 Therapeutics had approximately 97.6 million shares of common stock outstanding. The market value of its publicly traded shares (excluding insider holdings) was approximately $100 million as of June 30, 2025.

Strategic Collaborations and Milestones (Management Discussion Highlight)

Partnerships form a cornerstone of C4 Therapeutics' strategy, providing crucial funding, external validation, and shared development capabilities.

• Merck KGaA Agreement (March 2024): This collaboration offers potential discovery, regulatory, and commercial milestone payments plus tiered royalties on future sales.
• Betta Agreement (May 2023): This partnership provides for potential research and development milestones and drug application approval payments.
• Roche Agreement (Restated December 2018): This long-standing collaboration achieved a "lead series identification" milestone in November 2020. It offers potential for significant milestone payments and sales-based payments if a drug reaches the market.
• Biogen Research and License Agreement (February 2020): This partnership also includes potential research and development milestones and sales-based payments.

These collaborations are vital for reducing development risk, securing non-dilutive funding (capital that doesn't require issuing new shares), and accelerating the advancement of C4 Therapeutics' TPD programs.

Competitive Position

C4 Therapeutics operates within the highly competitive and rapidly evolving biotechnology industry, specifically in targeted protein degradation (TPD). Its competitive advantages stem primarily from:

• Proprietary Technology Platform: The company's TORPEDO™ platform identifies and develops novel TPD therapeutics, offering a differentiated approach to drug discovery. This platform forms a core asset underpinning its pipeline.
• Early-Mover Advantage in Specific Targets: By focusing on novel targets and mechanisms within TPD, C4 Therapeutics aims to establish leadership in certain disease areas or molecular pathways.
• Strong Intellectual Property Portfolio: The company actively protects its drug candidates, platform technology, and methods of use through patents and other intellectual property rights, crucial for maintaining a competitive edge.
• Strategic Collaborations: Partnerships with larger pharmaceutical companies like Merck KGaA, Roche, and Biogen provide external validation of its technology, access to broader resources, and shared development expertise. These collaborations can accelerate development and commercialization efforts.
• Experienced Management and Scientific Team: A team with deep expertise in drug discovery, development, and TPD science is critical for navigating the complexities of biotech innovation.

Despite these strengths, C4 Therapeutics faces intense competition from other biotechnology and pharmaceutical companies, many of which possess greater financial, technical, and human resources. Competitors also pursue TPD approaches, alongside traditional small molecule and biologic therapies. The company's ability to successfully advance its pipeline, secure regulatory approvals, and protect its intellectual property will be key to maintaining and improving its competitive standing.

Risk Factors and Future Outlook (Guidance, Strategy)

C4 Therapeutics faces inherent risks common to early-stage biotechnology companies:

• Clinical Development Risk: The success of its drug candidates remains highly uncertain, with a high failure rate at each stage of clinical trials. Positive preclinical data does not guarantee success in human trials.
• Regulatory Risk: Obtaining regulatory approvals (e.g., from the FDA) is a lengthy, expensive, and uncertain process.
• Funding Risk: The company is not yet profitable and will require substantial additional capital to fund its operations and advance its pipeline. Future equity financings will likely result in further dilution for existing shareholders, meaning each share represents a smaller ownership percentage.
• Competition: The targeted protein degradation field is highly competitive, with numerous companies pursuing similar approaches.
• Intellectual Property: Protecting its proprietary technology and drug candidates is crucial for long-term success.
• Dependence on Collaborations: A significant portion of its funding and development efforts rely on the success and continuation of its partnerships.
• "Smaller Reporting Company" and "Non-Accelerated Filer" Status: As a smaller reporting company and non-accelerated filer, C4 Therapeutics is subject to less stringent reporting requirements. This includes exemptions from certain disclosure obligations and internal control reporting, which some investors may perceive as a higher risk due to potentially less transparency.

Future Outlook: C4 Therapeutics will advance its internal and partnered pipeline programs, especially by moving its lead candidates through clinical trials and achieving key milestones. The company's ability to generate positive clinical data, secure additional funding, and effectively manage its collaborations will indicate its future progress and potential. Investors should closely monitor clinical trial readouts, partnership developments, and future financing activities.